IXICO CEO on growth, margins & TechBio strategy episode artwork

EPISODE · Apr 21, 2026 · 6 MIN

IXICO CEO on growth, margins & TechBio strategy

from Proactive - Interviews for investors · host Proactive Investors

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden joined Proactive's Stephen Gunnion to discuss a strong first half, with revenues up 23% to £3.9 million and gross margin expanding to 53%. Growth has been driven by new contract wins, extensions and rising demand for analytics across late-stage Alzheimer's, Parkinson's and rare CNS trials. The order book hit a multi-year high of £18.1 million - up 38% - giving strong visibility on future revenues. Following a £10 million fundraise, IXICO is now pursuing a TechBio strategy, licensing its platform to unlock recurring revenue streams and building strategic partnerships, including a recent collaboration with Medidata. For more insights into IXICO’s growth strategy and future outlook, visit Proactive’s YouTube channel, like this video, subscribe, and turn on notifications so you never miss an update. #IXICO #BramGoorden #BiotechStocks #HealthcareTech #TechBio #ClinicalTrials #AlzheimersResearch #ParkinsonsResearch #CNS #Biomarkers #Medidata #Investing #SmallCapStocks #LifeSciences #StockMarketNews

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden joined Proactive's Stephen Gunnion to discuss a strong first half, with revenues up 23% to £3.9 million and gross margin expanding to 53%. Growth has been driven by new contract wins, extensions and rising demand for analytics across late-stage Alzheimer's, Parkinson's and rare CNS trials. The order book hit a multi-year high of £18.1 million - up 38% - giving strong visibility on future revenues. Following a £10 million fundraise, IXICO is now pursuing a TechBio strategy, licensing its platform to unlock recurring revenue streams and building strategic partnerships, including a recent collaboration with Medidata. For more insights into IXICO’s growth strategy and future outlook, visit Proactive’s YouTube channel, like this video, subscribe, and turn on notifications so you never miss an update. #IXICO #BramGoorden #BiotechStocks #HealthcareTech #TechBio #ClinicalTrials #AlzheimersResearch #ParkinsonsResearch #CNS #Biomarkers #Medidata #Investing #SmallCapStocks #LifeSciences #StockMarketNews

NOW PLAYING

IXICO CEO on growth, margins & TechBio strategy

0:00 6:25

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Proactive - Interviews for investors?

This episode is 6 minutes long.

When was this Proactive - Interviews for investors episode published?

This episode was published on April 21, 2026.

What is this episode about?

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden joined Proactive's Stephen Gunnion to discuss a strong first half, with revenues up 23% to £3.9 million and gross margin expanding to 53%. Growth has been driven by new contract wins,...

Can I download this Proactive - Interviews for investors episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!